Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 341 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination pill Clear all

Conditions: Adult Attention-Deficit Hyperactivity Disorder
Interventions: Guanfacine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Contraception
Interventions: Cannabidiol Oil, Placebo, Combined oral contraceptive pill; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Actinic Keratosis
Interventions: Photodynamic therapy (PDT), Vitamin D3; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more

Conditions: Endometrioma
Interventions: Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Migraines, Bleeding, Spotting
Interventions: frovatriptan, placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Metastatic Prostatic Adenocarcinoma
Interventions: Opdivo Injectable Product, Yervoy Injectable Product, Cytoxan, Cryosurgical freezing (cryosurgery); Drug · Procedure
Lead sponsor: Rampart Health, L.L.C.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Lancaster, California • Rochester, Michigan

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide Pill; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 15 more

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral combined hormonal contraceptives; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years to 49 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HIV Seroconversion, Stimulant Abuse
Interventions: Truvada; Drug
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Post Traumatic Stress Disorder
Interventions: Brexpiprazole, Sertraline, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions: Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy; Drug · Procedure
Lead sponsor: Our Lady of the Lake Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
Interventions: MLN8237 and Erlotinib; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson's Disease, Dyskinesias, Movement Disorders
Interventions: Buspirone, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Menorrhagia
Interventions: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation; Drug · Device
Lead sponsor: Abimbola Famuyide; Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Methamphetamine Abuse, Methamphetamine Dependence
Interventions: Atomoxetine, then Placebo, Placebo, then Atomoxetine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Nonfluent Aphasia, Stroke
Interventions: levodopa/carbidopa, Placebo comparator; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 21 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Enzalutamide, exemestane, Placebo (for enzalutamide); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 89
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan plus Spironolactone, Ambrisentan plus Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Letrozole, Everolimus, TRC105; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension, Hyperlipidemia
Interventions: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks, Screening, OGTT, Anthropometrics and Blood pressure, Blood Drawing; Drug · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Galveston, Texas

Search by objective public record fields.

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).

Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

Evolutionary Therapy for Rhabdomyosarcoma

Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder

Rapid Atrial Fibrillation Treatment Strategy

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

Safety Assessment of Atomoxetine With MA IV Administration

Augmenting Language Therapy for Aphasia: Levodopa

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

The SCCS Polypill Pilot Trial

Effect of Lycopene and Isoflavones on Glucose Metabolism